

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Deuruxolitinib for treating severe alopecia areata ID6597**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Sun Pharma (deuruxolitinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Alopecia UK</li> <li>• British Hair and Nail Society</li> <li>• Changing Faces</li> <li>• Gene People</li> <li>• Genetic Alliance UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Association of Dermatologists</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Skin Foundation</li> <li>• British Society for Cutaneous Allergy</li> <li>• British Society for Genetic Medicine</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Pfizer (rituximab)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society of Immunology</li> <li>• Cochrane Skin Group</li> <li>• Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul> <p><u>Evidence Review Group</u></p>

Provisional stakeholder list for the evaluation of deuruxolitinib for treating severe alopecia areata ID6597

Issue date: December 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 1 of 3

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
	<ul style="list-style-type: none"> <li>National Institute for Health Research Health Technology Assessment Programme (NETSCC)</li> </ul> <p><u>Associated Guideline Group</u></p> <p>NICE - National Guideline Alliance (cancer, mental health, and women and children's health)</p> <p>NICE - National Guideline Centre (Acute Care, Chronic Conditions, Nursing and Supportive Care and Primary Care)</p>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Provisional stakeholder list for the evaluation of deuruxolitinib for treating severe alopecia areata  
ID6597

Issue date: December 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.